Corbus Pharmaceuticals
CRBP
85 hedge funds and large institutions have $45.6M invested in Corbus Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 22 increasing their positions, 29 reducing their positions, and 23 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.13% less ownership
Funds ownership: 1.32% → 1.19% (-0.13%)
11% less call options, than puts
Call options by funds: $763K | Put options by funds: $862K
13% less funds holding
Funds holding: 98 → 85 (-13)
24% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 29
50% less capital invested
Capital invested by funds: $90.6M → $45.6M (-$45M)
57% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$764K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$325K |
| 3 |
BlackRock
New York
|
+$269K |
| 4 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
+$193K |
| 5 |
HF
HRT Financial
New York
|
+$173K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IEFM
IQ EQ Fund Management
Dublin 2,
Ireland
|
-$3.41M |
| 2 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$1.17M |
| 3 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
-$877K |
| 4 |
Millennium Management
New York
|
-$745K |
| 5 |
Charles Schwab
San Francisco,
California
|
-$618K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Citigroup
New York
| – | -$15.1K | -384 | -99% |
|
|
PGWM
102
Parisi Gray Wealth Management
Mendham,
New Jersey
| – | -$2K | -36 | Closed |
|
|
SWM
103
Sugarloaf Wealth Management
Duluth,
Georgia
| – | -$2K | -33 | Closed |
|
104
New York State Common Retirement Fund
Albany,
New York
| – | -$1K | -20 | Closed |
|
CRBP Hedge Fund Activity: Q3 2021 in Review
85 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q3 2021, worth a combined $45.6M — down 50% from $90.6M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of CRBP and 10 opened new positions — a net loss of 13 holders — while 29 trimmed existing stakes and 22 added.
The largest buyer was Bank of America, adding an estimated $764K. The largest seller was IQ EQ Fund Management, cutting an estimated $3.41M.
- 85 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q3 2021, down from 98 in Q2 2021.
- Funds reported $45.6M of Corbus Pharmaceuticals stock for Q3 2021, down 50% quarter-over-quarter.
- 10 funds opened new Corbus Pharmaceuticals positions in Q3 2021 and 23 closed out, a net change of -13 holders.
- The largest Corbus Pharmaceuticals buyer in Q3 2021 was Bank of America, an estimated $764K added.
- The largest Corbus Pharmaceuticals seller in Q3 2021 was IQ EQ Fund Management, an estimated $3.41M sold.
Based on aggregated 13F filings for Q3 2021.